STX209 · program
Arbaclofen for Multiple sclerosis
- FDA Orphan Drug Designation (Alleviation Of Signs And Symptoms Of Spasticity Resulting From Multiple Sclerosis), Per Osmotica/RVL 10-K Filings; Grant Date Not Disclosed
Indications for STX209: Autism spectrum disorder · Phase 2 Multiple sclerosis · Phase 3 Fragile X syndrome · Phase 3
Arbaclofen extended-release tablets (Osmotica's Osmodex osmotic tablet, OS440) for spasticity in multiple sclerosis. This is a neurology program, not the lead, recorded for completeness. The first Phase 3 (OS440-3002, NCT01743651; arbaclofen 40 mg/day vs baclofen 80 mg/day vs placebo) was completed in 2014. According to Osmotica, an FDA audit then judged that trial's data insufficient to support a marketing application. The second Phase 3 (OS440-3004, NCT03290131; 536 patients, 40 or 80 mg/day for 12 weeks) significantly reduced TNmAS-MAL spasticity at 40 mg/day vs placebo (LS mean difference -0.39) but missed the co-primary CGIC endpoint. The NDA, first filed in 2015, was resubmitted in June 2020 with a 2020-12-29 goal date. FDA issued a Complete Response Letter on 2020-12-28: it found the statistical analysis of the 40 mg TNmAS-MAL co-primary endpoint inadequately justified and recommended a new study. A Type A meeting followed (2021-03-04), and a Special Protocol Assessment for a further trial was not agreed (FDA letter 2021-10-15). A new Phase 3 (OS440-3006, NCT05179577; 80 mg/day BID, 442 planned) is registered as not yet recruiting, with a January 2027 start. In its FY2022 10-K, RVL Pharmaceuticals said it was looking to sell or out-license arbaclofen ER. No later owner or development decision could be cited, so status is unknown.
Development timeline
- UpcomingClinicalTrials.gov estimated primary completion of Phase 3 OS440-3006 (NCT05179577), arbaclofen ER 80 mg/day vs placebo in MS spasticity: January 2028. The study is not yet recruiting, with an estimated January 2027 start.
- RVL Pharmaceuticals' FY2022 10-K says it is looking to sell or out-license arbaclofen ER tablets. No later disclosure of the program's owner or status was found.↗
- FDA regulatory meeting / outcomeFDA declines to agree a Special Protocol Assessment for a new arbaclofen ER study↗
- FDA Complete Response Letter, which recommends a new study to provide substantial evidence of efficacy. The program reverts to a Phase 3 requirement.↗
- Phase 3 OS440-3002 (NCT01743651) of arbaclofen tablets 40 mg/day vs baclofen and placebo in MS spasticity starts.
- Osmotica resubmits the arbaclofen ER NDA (first submitted in 2015) for spasticity in multiple sclerosis. FDA accepts it as a complete response to its 2016-07-09 action letter and sets a 2020-12-29 goal date.↗
Readouts
- January 2028AnticipatedRegistry resultsNCT05179577
ClinicalTrials.gov estimated primary completion of Phase 3 OS440-3006 (NCT05179577), arbaclofen ER 80 mg/day vs placebo in MS spasticity: January 2028. The study is not yet recruiting, with an estimated January 2027 start.
Clinical trials in Multiple sclerosis
NCT05179577OS440-3006Phase 3Activen=442
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006)
NCT03319732OS440-3005Phase 3Completedn=323
An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)
NCT03290131OS440-3004Phase 3Completedn=536
A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
NCT01743651OS440-3002Phase 3Completedn=353
A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis
Formulations
| Formulation | Route | Regimen | Pharmacokinetics |
|---|---|---|---|
| Arbaclofen extended-release tablets (Osmodex), 40 or 80 mg/day BIDOsmodex osmotic extended-release tablet Arbaclofen ER 40 mg/day or 80 mg/day in two daily doses (12-hour dosing interval) in the Phase 3 OS440-3004 study (NCT03290131). The planned OS440-3006 study (NCT05179577) uses 80 mg/day, twice daily. | Oral | Twice daily | — |
Mechanism of action
Selective orthosteric agonist of the GABA-B receptor, a Gi/o-coupled class C GPCR that works as a GABAB1/GABAB2 heterodimer; the agonist binds the GABAB1 subunit. Arbaclofen is the active R-enantiomer of baclofen, with 100- to 1000-fold greater GABA-B specificity than the S-enantiomer and about 5-fold greater potency than racemic baclofen. In the neurodevelopmental programs, the hypothesis is that GABA-B activation rebalances cortical excitation and inhibition and dampens excess glutamate release, which is implicated in fragile X syndrome (Fmr1 knockout models) and some autism. In spasticity, the effect comes from presynaptic inhibition of spinal reflexes, as with baclofen.
| Target | Action | Affinity |
|---|---|---|
| GABA-B receptorprimaryGABBR1 | Agonist | —ⓘ |
← Full STX209 compound page (identity, identifiers, all indications)
Sources
- NCT01743651 (OS440-3002) — Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT03290131 (OS440-3004) — A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT03319732 (OS440-3005) — A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS — ClinicalTrials.gov (U.S. National Library of Medicine)
- NCT05179577 (OS440-3006) — A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis — ClinicalTrials.gov (U.S. National Library of Medicine)
- Okuda DT, et al. Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial. Brain Commun 2022;4(6):fcac300 — Brain Communications (OUP) / PubMed
- Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. FDA for Arbaclofen Extended Release Tablets (8-K Ex. 99.1, 2020-12-29) — Osmotica Pharmaceuticals plc / SEC EDGAR
- RVL Pharmaceuticals plc Form 10-K for fiscal year 2021 (filed 2022-03-30) — RVL Pharmaceuticals plc / SEC EDGAR
- RVL Pharmaceuticals plc Form 10-K for fiscal year 2022 (filed 2023-03-20) — RVL Pharmaceuticals plc / SEC EDGAR